Indeed, Venetoclax, a selective BCL-2 inhibitor, has been the first BH3-mimetic approved for a subset of patients with Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia21,53,54. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.